Answers are grounded in this paper and cite their sources.
Desmoid-type fibromatosis (DTF) is a borderline soft-tissue tumor that, although preferably managed with active surveillance, frequently requires treatment due to local aggressive growth and/or complaints. Local non-resectional therapies have many advantages over traditional therapies. However, it remains challenging to select the most appropriate local non-resectional therapy in the heterogeneous desmoid population. Several patient- and tumor-related factors prevent some patients from being eligible for currently available local ablative and vascular therapies. Cryotherapy, high-intensity focused ultrasound (HIFU), and drug-eluting bead transarterial chemoembolization (DEB-TACE) are the currently available local non-resectional therapies that decrease tumor volume and pain scores with relatively low rates of complications. Advantages of these therapies are that they are relatively cheap compared with systemic therapy, can be repeated over time, and have subtle differences in their (contra)indications. Indications and treatment outcomes for cryotherapy and HIFU are grossly similar. However, cryotherapy seems feasible for more patients and is better studied compared with HIFU. Alternatively, HIFU is less invasive and can be carried out in select cases of intra-abdominal DTF. For ablative therapies, there is a risk of thermal damage to critical structures that are encased by the tumor or lie in close proximity. Especially in these cases, DEB-TACE may be suitable as this endovascular technique relies on the tumor's vasculature. Based on the currently available literature and clinical experience, we propose a flow diagram to guide in the decision-making process of local, non-resectional therapies for DTF.
No takes yet. Share an insight, caveat, or question.
Hakkesteegt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: